PASW Ping An Biomedical Co Ltd.

Huge upcoming alert🚨💹🔔 Before Market close, I will announce another stock to go with $PASW both can ve huge tomorrow 💰💹🔔 Give me a like if you’re ready. I need 50 likes to announce .”🚨🔔💹

$PASW 💰🚨💹🔔 HONG KONG 🇭🇰 small float ✅ Massive $500 news 💹 Definitely $PASW can be the next Hong Kong $MI which ran 600%

$PASW ai tells me Ping An Biomedical Co., Ltd. (PASW) will execute a 1-for-40 reverse stock split tomorrow, Friday, October 23, 2026. so it might be closed tomorrow for a while for trading.

$PASW is active on M&A / acquisition following a Globe Newswire release. Ping An Biomedical plans to acquire three tumor cell-related medical technology patents from Future Biotechnology Group for $2-2.5 million to build its oncology IP portfolio. RTPR pushed this release out to users at 3:30:00 PM ET

$PASW 🚨 power hours alert 💰💹🔔 HONG KONG 🇭🇰 small float ✅ Massive $500 million news 💹 Definitely $PASW can be the next Hong Kong $MI which ran 1000%

$PASW ratifies a 40-for-1 share consolidation approved at its extraordinary general meeting.

$PASW — Ping An Biomedical's reverse stock split and patent acquisition contrasted with declining financials and mixed technical signals. Upside discussed: Positive short-term price momentum indicated by 10-day EMA above 50-day SMA. Strong buying pressure suggested by a high Money Flow Index (MFI). Recent upward price movement over 7-day and 30-day periods. Risk discussed: Significant year-over-year revenue decline of -47.4% and -62%. Negative Earnings Per Share (EPS) and Profit Margin. Weak long-term trend indicated by price below the 200-day SMA. Recent analyses for PASW covered a 1-for-40 reverse stock split and the acquisition of oncology-related patents, alongside a strategic cooperation agreement aimed at significant sales targets. These developments were examined against a backdrop of declining revenues, negative profitability metrics, and mixed technical indicators, including short-term upward momentum contrasted with a weaker long-term trend.

$PASW 🤝 Ping An Biomedical Co., Ltd entered into a letter of intent to acquire three tumor cell-related medical technology patents from Future Biotechnology Group Co., Limited for US$2 million to US$2.5 million, subject to a final acquisition agreement, to build an oncology and biotech intellectual property portfolio. Timely market event